{
  "timestamp": "2026-02-21T14:20:00.550010+00:00",
  "feed_lines": 193,
  "recent_feed": [
    "{\"timestamp\":\"2026-02-21T03:55:44Z\",\"topic\":\"self-improvement\",\"insights\":[\"No new developments\"],\"tools_used\":[\"web_search\"],\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"2026-02-21T03:57:19Z\",\"topic\":\"self-improvement\",\"insights\":[\"No new developments\"],\"tools_used\":[\"web_search\"],\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{'timestamp': '2026-02-21T03:58:38Z', 'topic': 'self-improvement', 'insights': ['No new developments'], 'tools_used': ['web_search'], 'files_updated': ['memory/learning-feed.jsonl']}",
    "{\"timestamp\":\"2026-02-21T04:00:03Z\",\"topic\":\"self-improvement\",\"insights\":[\"No new developments\"],\"tools_used\":[\"web_search\"],\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"$(date -u +%Y-%m-%dT%H:%M:%SZ)\",\"topic\":\"ai-agents\",\"insights\":[\"Microsoft Agent Framework reaches Release Candidate with migration paths from Semantic Kernel/AutoGen\",\"Multi-provider support (OpenAI, Ollama, Azure) included\",\"New graph-based workflow engine for multi-agent orchestration\"],\"tools_used\":[\"web_search\",\"web_fetch\",\"exec\"],\"files_updated\":[\"memory/learning-feed.jsonl\",\"memory/knowledge.db\"]}",
    "{\"timestamp\":\"2026-02-21T15:30:00Z\",\"topic\":\"longevity research\",\"subtopic\":\"p-tau217 blood test commercial availability\",\"tools_used\":[\"web_search\"],\"insights\":[\"FDA cleared first Alzheimer's blood test (Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio) in May 2025 - enables Medicare and private insurer coverage\",\"Labcorp offers standalone pTau-217 plasma test (test code 484390) and pTau-217/Beta Amyloid 42 ratio test with physician order\",\"Lucent Diagnostics offers LucentAD p-Tau 217 multi-biomarker test using Simoa technology\",\"Mayo Clinic Labs offers Phospho-Tau 217 Plasma test (PT217) for individuals 50+ years\",\"Genova Diagnostics offers Alzheimer's Assessment p-Tau217 blood test\",\"TrueHealthLabs.com allows online ordering of p-tau217\",\"ALZpath, C2N Diagnostics, Fujirebio Diagnostics, Quest Diagnostics, ADx Health also offer testing\",\"Cost ranges approximately $195-$400 depending on provider; FDA clearance should expand insurance coverage\"],\"sources\":[\"https://www.labcorp.com/tests/484390/phosphorylated-tau-217-ptau-217-plasma\",\"https://www.lucentdiagnostics.com/tests/lucentad-p-tau-217/\",\"https://www.mayocliniclabs.com/test-catalog/Overview/621635\",\"https://beingpatient.com/how-much-is-an-alzheimers-blood-test/\",\"https://www.ncbiotech.org/news/first-fda-cleared-alzheimers-blood-test-now-available-labcorp\"],\"quality_score\":9,\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"2026-02-21T15:31:00Z\",\"topic\":\"longevity research\",\"subtopic\":\"AKL003 Klothea Bio Phase 1b trial\",\"tools_used\":[\"web_search\"],\"insights\":[\"Klothea Bio announced Phase 1b trial launch on 2026-02-19 (two days ago) - actively recruiting\",\"Trial is randomized double-blind placebo-controlled evaluating AKL003 alpha Klotho mRNA therapeutic\",\"AKL003 is alpha Klotho mRNA formulated in lipid nanoparticles administered IV with saline placebo\",\"Population: healthy adults ages 25-75; two administrations approximately 4 weeks apart; 2:1 randomization (AKL003:placebo)\",\"Primary objective: safety and tolerability; secondary: serum alpha Klotho protein levels over time\",\"Exploratory: inflammatory markers, metabolic/cardiovascular measures, sleep quality (wearable data), QoL questionnaires\",\"Single study site at GARM Clinic in special jurisdiction of Prospera Roatan Honduras - NOT registered on ClinicalTrials.gov\",\"Participants must travel to Roatan Honduras for study participation\",\"ClinicalTrials.gov listing NCT07216781 exists but unclear if this is the same study\"],\"sources\":[\"https://www.globenewswire.com/news-release/2026/02/19/3241223/0/en/Klothea-Bio-Announces-the-Launch-of-a-Phase-1b-Clinical-Trial-of-AKL003-an-Alpha-Klotho-mRNA-Therapeutic-for-the-Extension-of-Human-Lifespan.html\",\"https://clinicaltrials.gov/study/NCT07216781\",\"https://klothea.com/\",\"https://trial.medpath.com/news/575d90bcf2bf660a/klothea-bio-launches-phase-1b-trial-of-akl003-mrna-therapy-targeting-longevity-protein-klotho\"],\"quality_score\":8,\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"2026-02-21T15:32:00Z\",\"topic\":\"longevity research\",\"subtopic\":\"DMTF1 neural stem cell rejuvenation\",\"tools_used\":[\"web_search\"],\"insights\":[\"Original study published in Science Advances January 2026 (DOI: 10.1126/sciadv.ady5905) by NUS Yong Loo Lin School of Medicine\",\"DMTF1 (cyclin D-binding myb-like transcription factor 1) levels significantly reduced in aged neural stem cells\",\"Restoring DMTF1 expression rescued proliferation defect via SWI/SNF-E2F axis\",\"Mechanism: DMTF1 regulates transcription of Arid2 and Ss18 genes (SWI/SNF complex subunits) that mediate H3K27ac at E2F gene promoters\",\"Full paper title: DMTF1 up-regulation rescues proliferation defect of telomere dysfunctional neural stem cells via the SWI/SNF-E2F axis\",\"PubMed ID: 41481722; PMC: PMC12758551\",\"No follow-up studies found yet - original paper is only ~6 weeks old (published Jan 2026)\",\"Next steps identified by researchers: screening small molecules to safely stimulate DMTF1 activity\"],\"sources\":[\"https://www.science.org/doi/10.1126/sciadv.ady5905\",\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12758551/\",\"https://pubmed.ncbi.nlm.nih.gov/41481722/\",\"https://www.sciencedaily.com/releases/2026/02/260212025620.htm\",\"https://phys.org/news/2026-01-key-protein-aging-neural-stem.html\"],\"quality_score\":8,\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"2026-02-21T15:33:00Z\",\"topic\":\"longevity research\",\"subtopic\":\"metformin exercise blunting RCT data\",\"tools_used\":[\"web_search\"],\"insights\":[\"MASTERS Trial (2019 baseline, still definitive): 1700mg/day metformin vs placebo with 14 weeks progressive resistance training; placebo gained significantly more lean body mass (p=.003) and thigh muscle mass (p<.001)\",\"NEW 2025 Rutgers RCT: metformin 2000mg/d blunts vascular insulin sensitivity improvements after 16 weeks exercise training in adults at risk for metabolic syndrome; blunted cardiorespiratory fitness gains by approximately 50%\",\"NEW 2025 MET-PREVENT Trial (Lancet Healthy Longevity): In healthy older adults metformin blunted both strength and endurance outcomes from exercise training; in older men with prefrailty/sarcopenia effects were mixed\",\"Mechanism: metformin blocks mitochondrial complex I reducing oxidative stress but same inhibition interferes with exercise-induced mitochondrial adaptations and aerobic capacity improvements\",\"Consensus building: multiple RCTs now show metformin blunts exercise benefits across resistance training, aerobic training, and combined modalities\",\"Clinical implication: timing separation of metformin and exercise may be necessary; healthy non-diabetic individuals using metformin for longevity should weigh exercise blunting costs\"],\"sources\":[\"https://pubmed.ncbi.nlm.nih.gov/41160096/\",\"https://www.rutgers.edu/news/why-your-daily-walk-might-not-work-well-if-youre-metformin\",\"https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00014-5/fulltext\",\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6826125/\",\"https://www.pharmacytimes.com/view/metformin-may-diminish-the-cardiometabolic-benefits-of-exercise\"],\"quality_score\":9,\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":\"2026-02-21T15:34:00Z\",\"topic\":\"AI agent architectures\",\"subtopic\":\"ring attention million-token context production\",\"tools_used\":[\"web_search\"],\"insights\":[\"Meta achieved 1M-token prefill in 77 seconds on single H100 host and sub-1-minute 10M-token prefill across distributed H100 hosts using ring attention with Pass-KV approach\",\"Production models with million-token windows now shipping: Meta Llama 4 Scout (10M tokens), Google Gemini (1M tokens), Claude (1M beta)\",\"Ring Attention reduces memory complexity from O(n^2) to O(n) by processing attention in localized windows while maintaining global context through information propagation\",\"Context parallelism degree-4 enables sequences 3-4x longer than single-GPU limits but communication overhead prevents linear scaling\",\"Enterprise deployment of 5-10M token context windows expected practical by late 2026 for document analysis, code comprehension, scientific research\",\"Hardware enablers: HBM3e memory and NVLink 4.0 interconnects critical for ring attention performance at scale\"],\"sources\":[\"https://engineering.fb.com/2025/10/17/ai-research/scaling-llm-inference-innovations-tensor-parallelism-context-parallelism-expert-parallelism/\",\"https://www.exxactcorp.com/blog/deep-learning/how-llms-reach-large-token-context-windows\",\"https://johal.in/llm-context-windows-ring-attention-for-2026-long-sequence-processing-2/\",\"https://introl.com/blog/long-context-llm-infrastructure-million-token-windows-guide\",\"https://www.micron.com/about/blog/company/insights/1-million-token-context-the-good-the-bad-and-the-ugly\"],\"quality_score\":7,\"files_updated\":[\"memory/learning-feed.jsonl\"]}",
    "{\"timestamp\":2026-02-21T12:56:06Z,\"topic\":\"longevity\",\"insights\":\"[\"No new PEARL trial dose-response data available as of 2026-02-21\",\"RAP-2026-02-20-1: Rapamycin immune benefits in older adults not dose-quantified\",\"Gold Bamboo review confirms pending human trial outcomes but no new 6.19kg lean mass sustainability data\"]\",\"tools_used\":\"[\"web_search\",\"exec\"]\",\"files_updated\":\"[\"memory/learning-feed.jsonl\"]\"}",
    "{\"timestamp\":\"2026-02-21T12:57:00Z\",\"topic\":\"treasury-bonds\",\"insights\":[\"RIKB 28 1115 auctioned 2.945 billion with bid-to-cover 1.70 and indirect bidders 48%\",\"RIKB 38 0215 auctioned 6.352 billion with bid-to-cover 1.05 and indirect bidders 48%\"],\"tools_used\":[\"web_search\",\"web_fetch\"],\"files_updated\":[\"memory/learning-feed.jsonl\",\"memory/knowledge.db\"]}",
    "{\"timestamp\":\"$(date -u +\"%Y-%m-%dT%H:%M:00Z\" 2>/dev/null || date -u +\"%Y-%m-%dT%H:%M:00Z\")\",\"topic\":\"ai-agents\",\"insights\":[\"Microsoft Agent Framework introduces workflows\",\"Combines Semantic Kernel and AutoGen\"],\"tools_used\":[\"web_search\",\"web_fetch\",\"exec\"],\"files_updated\":[\"memory/learning-feed.jsonl\",\"memory/knowledge.db\"]}",
    "{\"timestamp\":\"$(date -u +%Y-%m-%dT%H:%M:%SZ)\",\"topic\":\"self-improvement\",\"insights\":[\"novelty-seeking mechanisms linked to habit formation (0.85 confidence)\",\"environmental cues shown to enhance memory retention (0.78 confidence)\"],\"tools_used\":[\"web_search\",\"web_fetch\",\"exec\"],\"files_updated\":[\"memory/learning-feed.jsonl\",\"memory/knowledge.db\"]}",
    "{\"timestamp\":\"$(date -u +%Y-%m-%dT%H:%M:%SZ)\",\"topic\":\"tool-calling\",\"insights\":[\"No new developments\",\"Ollama 0.7.0 not released\",\"qwen3-32b-32k benchmarks saturated\"],\"tools_used\":[\"web_search\"],\"files_updated\":[\"memory/learning-feed.jsonl\"]}"
  ],
  "kg_stats": "Entities: 77\nRelationships: 61\nAssociations: 9\nInsights: 0\nDomains: {\n  \"treasury-bonds\": 24,\n  \"tool-calling\": 18,\n  \"ai-agents\": 10,\n  \"cross-domain\": 9,\n  \"longevity\": 8,\n  \"self-improvement\": 4,\n  \"local model inference\": 2,\n  \"treasury\": 2\n}",
  "last_synthesis": "daily-synthesis-2026-02-21.md",
  "synthesis_content": "# Daily Synthesis - 2026-02-21\n\nGenerated by: zeke-reason.sh (Claude Code autonomous reasoning layer)\nFeed entries analyzed: 183 total, 20 most recent scored\nKG state: 65 entities, 51 relationships, 7 domains\n\n---\n\n## 3 Key Strategic Insights\n\n### 1. PRIORITY - TLT: Hawkish pause + 20-year at 4.85% = compressed entry window\n\nThe overnight feeds confirm two data points that directly affect Matt's TLT LEAPS:\n- 10-year yield surged to 4.1% after Fed minutes confirmed hawkish pause\n- 20-year Treasury (DGS20) at 4.85% as of 2/19/2026\n- January payrolls came in at 130,000 (below 150k trend) - modestly softening labor\n\nImplication for TLT LEAPS (all exp 1/15/27):\n- TLT currently priced for yields staying elevated. If the hawkish pause ends earlier\n  than expected (e.g., PCE softens in March), TLT could rally 8-12% rapidly.\n- The $90C (650x) and $95C (300x) positions have the highest probability of finishing\n  ITM if yields decline 75-100bps from current 4.85% (20-year) to ~3.85-4.10%.\n- The $101C (3150x) requires a more aggressive move - yields would need to fall to\n  approximately 3.5% or below (TLT >$101) - this needs a recession catalyst or\n  significant Fed pivot, not just a pause.\n- WATCH: Next PCE release and FOMC meeting. The ODonnell Financial 66% TLT stake\n  reduction (Q3 2026 - note: this timestamp appears forward-dated, verify) is a\n  potential institutional positioning signal worth monitoring.\n\nAction: Run a duration/convexity model on TLT price at various yield scenarios.\nSpecifically: at 4.0%, 3.75%, and 3.5% 20-year yields, what does TLT price to?\nThis determines which LEAPS tranches are in-the-money at expiry.\n\n### 2. Longevity: Two high-signal findings from overnight research\n\nFinding A - Rapamycin PEARL Trial (NCT04488601):\n10mg/week rapamycin in women aged 50-85 produced 6.19kg lean mass gain over 48 weeks\nin a randomized double-blind trial. This is the strongest human evidence to date for\nrapamycin's body composition effects beyond lifespan extension. The dose (10mg/week)\nis higher than typical human longevity protocols (2-6mg/week). This creates a research\nquestion: what is the dose-response relationship between 2mg and 10mg for lean mass?\n\nFinding B - p-tau217 blood test:\nCan predict Alzheimer's symptom onset 3-4 years before clinical presentation.\nThis represents an actionable early-warning window. The test measures a specific\nphosphorylated tau protein isoform. Commercial availability is now the key question.\nIf available, this test would be a tier-1 longevity monitoring metric.\n\nCross-domain note: AKL003 (alpha-Klotho mRNA therapeutic from Klothea Bio) has\nentered Phase 1b trials. The mRNA delivery mechanism parallels rapamycin's intermittent\ndosing approach for biological effect optimization. Both target mTOR/aging pathways\nthrough different mechanisms - worth tracking for combination protocol potential.\n\n### 3. AI Agents: Microsoft framework RC + Zeke self-improvement opportunity\n\nMicrosoft's Agent Framework reaching Release C",
  "priorities_updated": "2026-02-21T12:42:10.176058+00:00",
  "priorities_content": "# Research Priorities - Updated 2026-02-21\n\nLast updated by: zeke-reason.sh (Claude Code autonomous reasoning)\nEvaluation basis: 20 feed entries scored, avg novelty 2.05/5.0\n\n---\n\n## P1 \u2014 HIGHEST VALUE (execute tonight)\n\n### Longevity (CRITICAL GAP - 5 KG entities, high novelty when researched)\nSpecific questions ranked by expected value:\n\n1. Rapamycin PEARL trial follow-up: Is there dose-response data below 10mg/week? What adverse\n   effects were observed? Is the 6.19kg lean mass gain sustained at 52+ weeks?\n   Source to check: ClinicalTrials.gov NCT04488601 updates, Blagosklonny 2026 commentary.\n\n2. p-tau217 blood test commercial availability: Which labs currently offer it? What is the\n   cost and turnaround? How does it compare to Elecsys pTau-217 vs Lumipulse assays?\n\n3. AKL003 Phase 1b trial enrollment status: Is Klothea Bio actively recruiting? What are\n   the eligibility criteria? Expected completion date?\n\n4. Metformin + exercise interaction: Does metformin blunt the longevity benefits of exercise\n   (AICAR pathway conflict)? This is a critical protocol question for Matt.\n\n5. NAD+ precursor head-to-head: Is there a 2025-2026 RCT comparing NR vs NMN vs precursor\n   in humans aged 50+? We have mechanism but no comparative human data in KG.\n\n### AI Agents (HIGH VALUE - 8 KG entities, Microsoft framework RC is significant)\n1. Microsoft Agent Framework RC: What specifically changed from Semantic Kernel? What is the\n   migration path from AutoGen v0.4? Is there a local/Ollama backend supported?\n\n2. Agent memory persistence: What is the current best architecture for agents that maintain\n   state across restarts without relying on external vector DBs? (Directly applies to Zeke)\n\n3. Multi-agent cost routing: What are production-measured cost savings from routing simple\n   tasks to 8B models vs 32B? We need empirical data not estimates.\n\n---\n\n## P2 \u2014 MEDIUM VALUE (apply existing knowledge to positions)\n\n### Treasury Bonds (21 KG entities, well-covered - now apply to T",
  "evaluation_count": 20,
  "recent_evaluations": [
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 11, \"feed_ts\": \"2026-02-20T19:13:37-0500\", \"topic\": \"longevity research\", \"insight_summary\": \"p-tau217 blood test predicts Alzheimer's onset within 3-4 years\", \"novelty_score\": 5, \"reasoning\": \"Named biomarker, specific predictive window, clinically actionable\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 12, \"feed_ts\": \"2026-02-20T21:00:00-05:00\", \"topic\": \"longevity research\", \"insight_summary\": \"5 minutes daily exercise reduces premature mortality by 6-10%; Lancet study 135k adults\", \"novelty_score\": 4, \"reasoning\": \"Named journal, large sample size, quantified mortality reduction\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 13, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"cross-domain-associations\", \"insight_summary\": \"EnergyTech_2026 cross-domain link 0.75 similarity score\", \"novelty_score\": 1, \"reasoning\": \"Malformed timestamp (literal shell variable), vague EnergyTech domain not tracked\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 14, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"tool-calling\", \"insight_summary\": \"Qwen3 MoE variant uses 30B parameters; Qwen3-Next support in llama.cpp\", \"novelty_score\": 3, \"reasoning\": \"Malformed timestamp, but specific model info relevant to Spark stack\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 15, \"feed_ts\": \"2026-02-21T03:54:42Z\", \"topic\": \"self-improvement\", \"insight_summary\": \"No new developments\", \"novelty_score\": 0, \"reasoning\": \"Explicitly no findings, malformed JSON (single quotes)\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 16, \"feed_ts\": \"2026-02-21T03:55:44Z\", \"topic\": \"self-improvement\", \"insight_summary\": \"No new developments\", \"novelty_score\": 0, \"reasoning\": \"Explicitly no findings - 4th consecutive dry run\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 17, \"feed_ts\": \"2026-02-21T03:57:19Z\", \"topic\": \"self-improvement\", \"insight_summary\": \"No new developments\", \"novelty_score\": 0, \"reasoning\": \"Explicitly no findings - 5th consecutive dry run\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 18, \"feed_ts\": \"2026-02-21T03:58:38Z\", \"topic\": \"self-improvement\", \"insight_summary\": \"No new developments\", \"novelty_score\": 0, \"reasoning\": \"Explicitly no findings, malformed JSON (single quotes)\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 19, \"feed_ts\": \"2026-02-21T04:00:03Z\", \"topic\": \"self-improvement\", \"insight_summary\": \"No new developments\", \"novelty_score\": 0, \"reasoning\": \"Explicitly no findings - 6th consecutive dry run\"}",
    "{\"timestamp\": \"2026-02-21T12:41:24Z\", \"eval_date\": \"2026-02-21\", \"feed_entry_idx_from_tail20\": 20, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"ai-agents\", \"insight_summary\": \"Microsoft Agent Framework RC with migration from Semantic Kernel/AutoGen\", \"novelty_score\": 4, \"reasoning\": \"Named framework, specific release milestone, actionable migration path info\"}"
  ],
  "self_heal_log": "",
  "ops_status": "",
  "zeke-queue_tail": [
    "Error: gateway timeout after 600000ms",
    "Gateway target: ws://127.0.0.1:18789",
    "Source: local loopback",
    "Config: /Users/zekezirk/.openclaw/openclaw.json",
    "Bind: loopback",
    "EXTRACT FAILED",
    "[14:07:07] ASSOCIATE",
    "Error: gateway timeout after 600000ms",
    "Gateway target: ws://127.0.0.1:18789",
    "Source: local loopback",
    "Config: /Users/zekezirk/.openclaw/openclaw.json",
    "Bind: loopback",
    "ASSOCIATE FAILED",
    "[14:17:08] REASON (Claude Code CLI - Opus)",
    "[Sat Feb 21 09:17:09 EST 2026] Running reasoning via Claude Code CLI (Max/Opus)"
  ],
  "zeke-reason-error_tail": [],
  "cron_job_count": 29
}